Difference between revisions of "Programmed death-ligand 1"

From Libre Pathology
Jump to navigation Jump to search
(Created page with "'''Programmed death-ligand 1''', commonly abbreviated '''PD-L1''', is protein with an important role in immune system regulation, and thus cancer aggressiveness. It is a...")
 
Line 2: Line 2:


It is also known as '''CD274'''.<ref name=omim>{{OMIM|605402}}</ref>
It is also known as '''CD274'''.<ref name=omim>{{OMIM|605402}}</ref>
PD-L1 antibodies are being used to treat:<ref name=pmid26895815>{{Cite journal  | last1 = Gandini | first1 = S. | last2 = Massi | first2 = D. | last3 = Mandalà | first3 = M. | title = PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. | journal = Crit Rev Oncol Hematol | volume = 100 | issue =  | pages = 88-98 | month = Apr | year = 2016 | doi = 10.1016/j.critrevonc.2016.02.001 | PMID = 26895815 }}</ref>
*[[Malignant melanoma]].
*[[non-small cell lung cancer]].
*[[Renal cell carcinoma]].


==See also==
==See also==

Revision as of 03:33, 4 May 2016

Programmed death-ligand 1, commonly abbreviated PD-L1, is protein with an important role in immune system regulation, and thus cancer aggressiveness.

It is also known as CD274.[1]

PD-L1 antibodies are being used to treat:[2]

See also

References

  1. Online 'Mendelian Inheritance in Man' (OMIM) 605402
  2. Gandini, S.; Massi, D.; Mandalà, M. (Apr 2016). "PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis.". Crit Rev Oncol Hematol 100: 88-98. doi:10.1016/j.critrevonc.2016.02.001. PMID 26895815.